GGrantIndex
← Search

Clinical Protocol and Data Management

$284,088P30FY2018CANIH

University Of California At Davis, Davis CA

Investigators

Linked publications, trials & patents

Paper 39725713Paper 39620216Paper 39616300Paper 39488208Paper 39453739Paper 39440945Paper 39384967Paper 39383000Paper 39350111Paper 39345479Paper 39345391Paper 39257973Paper 39252929Paper 39217266Paper 39177582Paper 39168154Paper 39108503Paper 39103353Paper 39056190Paper 39046599Paper 39012466Paper 38990223Paper 38979288Paper 38969563Paper 38947002Paper 38885336Paper 38877132Paper 38865710Paper 38843382Paper 38826195Paper 38803393Paper 38798575Paper 38780011Trial NCT07304011Trial NCT07258446Trial NCT07209215Trial NCT07189195Trial NCT07145112Trial NCT06905509Trial NCT06854159Trial NCT06211335Trial NCT06178354Trial NCT06173362Trial NCT06173349Trial NCT06103682Trial NCT06103669Trial NCT06067776Trial NCT05967533Trial NCT05843448Trial NCT05600686Trial NCT05479578Trial NCT05110781Trial NCT05101356Trial NCT05052528Trial NCT04964505Trial NCT04905810Trial NCT04856189Trial NCT04716699Trial NCT04587687Trial NCT04578600Trial NCT04552704Trial NCT04450173Trial NCT04410302Trial NCT04186988Trial NCT04050085Trial NCT04030559Trial NCT03695250Trial NCT03359460Trial NCT03299088Trial NCT03164486Trial NCT03123978Trial NCT02997761Trial NCT02935205Trial NCT02823990Trial NCT02807805Trial NCT02569723Trial NCT02400814Trial NCT02364609Trial NCT02348255Trial NCT02339168Trial NCT02178241Trial NCT02077998Trial NCT01924260Trial NCT01923337Trial NCT01911507Trial NCT01008566Trial NCT00918645Trial NCT00810719Trial NCT00804310Trial NCT00795665Trial NCT00628654Trial NCT00467077Trial NCT00408499Trial NCT00390429Trial NCT00389922Trial NCT00388115Trial NCT00388089Trial NCT00387660Trial NCT00387322Trial NCT00376727

Abstract

PROJECT SUMMARY/ABSTRACT Part I: Clinical Protocol and Data Management. The UCDCCC Office of Clinical Research (OCR), formerly the Clinical Trials Support Unit, is led by Associate Director for Clinical Research (Karen Kelly, MD) and OCR Executive Director (Cinda Lyon, RN). The OCR includes five units: operations, business, regulatory, phase I and clinical, thus providing cancer center investigators with a centralized resource providing a full repertoire of services to conduct clinical trials. The OCR staff work cohesively with the Investigators to provide subjects with exceptional care such that toxicities are minimized, trial adherence is maintained and data quality is achieved. Part II: Data and Safety Monitoring. All clinical trials conducted under the auspices of UCDCCC include provisions for data and safety monitoring. The Data Safety and Monitoring Plan (DSMP) focuses on patient safety, protocol adherence and quality of data. It was recently revised to provide oversight of clinical trial conduct in accordance with NCI guidelines. Part III: Inclusion of Minorities and Women in Clinical Trials. The UCDCCC is dedicated to the inclusion of women and minorities in our cancer clinical trials and complies with the NIH regulations on accrual of these populations. Entry criteria for cancer studies are disease, not gender or ethnicity specific. The sex/gender and racial/ethnic makeup of the study population for any one trial will be influenced by the frequency of the diagnosis in various subgroups. We offer clinical trials focused on cancers for which minority populations experience disparities, for example, liver cancer (Asian Americans and all populations of color), prostate cancer (African Americans and Hispanics), and breast cancer (African Americans, Hispanics, and Asian Americans). Although protocols are open to women who meet the eligibility criteria, pregnant and nursing women are excluded because of unknown risks of anti-neoplastic agents to fetuses and infants. Part IV: Inclusion of Children in Clinical Trials. UCDCCC, through the Pediatric Oncology Division, offers a large variety of clinical cancer research trials to the children of Sacramento and the surrounding area. These trials address a wide variety of pediatric malignancies, including (but not limited to) leukemia/lymphoma, osteosarcoma, Wilms Tumor and neuroblastoma.

View original record on NIH RePORTER →